Motif Bio PLC Update on Share Consolidation & Admission Warrants (5579A)

TIDMMTFB

RNS Number : 5579A

Motif Bio PLC

02 June 2021

2 June 2021

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA, THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN MOTIF BIO PLC OR ANY OTHER ENTITY IN ANY JURISDICTION.

Motif Bio plc

("Motif" or the "Company")

Update on Share Consolidation and Admission Warrants

Motif Bio plc (AIM: MTFB), which has been reclassified as an AIM Rule 15 cash shell, provides an update on the Share Consolidation and Admission Warrants that were detailed in its announcement of 26 May 2021.

The Company's current issued share capital of 654,991,023 will be adjusted through a proposed Share Consolidation to 2,977,231 New Ordinary Shares. The Company will issue 27,502,645 Consideration Shares for the proposed acquisition of BiVictriX (the "Acquisition"). On a primary basis, prior to the concurrent GBP10.1 million Fundraising, the Company will have 30,479,876 New Ordinary shares outstanding and issued.

As additional consideration, Admission Warrants over 1,488,615 New Ordinary Shares are to be issued for the benefit of existing Motif shareholders.

The Admission Warrants will be granted on the basis of one Admission Warrant per two New Ordinary Shares held immediately prior to completion of the Acquisition, with an exercise price of 30 pence and valid for 180 days following Admission which is expected to be on or around 8.00 a.m. on 15 June 2021.

The Admission Warrants will not be listed or admitted to trading, are not freely transferable and will be issued to existing Motif shareholders in certificated form by 25 June 2021.

The Acquisition details, as provided above, are all conditional on Shareholder support of all Resolutions at the General Meeting. For additional information on the Acquisition, please see the Admission Document which is posted on the Company's website (www.motifbio.com).

As all Resolutions to be voted on at the General Meeting are conditional, all Resolutions must be approved by shareholders for the Acquisition to proceed. Motif Bio plc will not be able to continue operations in the absence of this Acquisition. As a result, if all Resolutions are not approved by shareholders, it is expected that Motif's shares would be de-listed from the AIM market and Shareholders would receive no further value.

Expected Timetable of Principal Events

 
  Time and date of the General Meeting                 12.00 p.m. on 14 
                                                        June 2021 
 Announcement of the result of the General Meeting     14 June 2021 
 Record date for the issue of the Admission Warrants   6.00 p.m. on 14 
                                                        June 
 Ex-date of the issue of the Admission Warrants        15 June 2021 
 Despatch of Admission Warrant certificates            By 25 June 2021 
 

The Admission Document and further information on the Company can be found on Motif's website at: www.motifbio.com

Capitalised terms used in this announcement carry the same meanings as those ascribed to them in the Company's Admission Document dated 26 May 2021 and/or the Company's announcement of 26 May 2021, unless the context requires otherwise.

For further information please contact:

 
                                                       [e-mail] 
   Motif Bio plc 
 Jonathan Gold (Non-Executive Director) 
                                              ------------------------ 
 
 SP Angel Corporate Finance LLP (NOMAD 
  & BROKER)                                       [phone] 
                                              ------------------------ 
 David Hignell/Caroline Rowe (Corporate 
  Finance) 
                                              ------------------------ 
 Vadim Alexandre/Rob Rees (Sales & Broking) 
                                              ------------------------ 
 
 Walbrook PR Ltd. (UK FINANCIAL PR & 
  IR)                                             [phone] 
                                              ------------------------ 
 Paul McManus/ Lianne Cawthorne                [e-mail] 
                                              ------------------------ 
 
 

Forward-Looking Statements

This announcement may contain forward-looking statements. Words such as "expects", "anticipates", "may", "should", "would", "could", "will", "intends", "plans", "believes", "targets", "seeks", "estimates", "aims", "projects", "pipeline" and variations of such words and similar expressions are intended to identify such forward-looking statements and expectations. These statements are not guarantees of future performance or the ability to identify and consummate transactions and involve certain risks, uncertainties, outcomes of negotiations and due diligence and assumptions that are difficult to predict, qualify or quantify. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements or expectations. Among the factors that could cause actual results to differ materially are: the general economic climate, competition, interest rate levels, loss of key personnel, the result of legal and commercial due diligence and changes in the legal or regulatory environment.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDSSSSAEEFSEEM

(END) Dow Jones Newswires

June 02, 2021 04:32 ET (08:32 GMT)